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AbstrACt
Introduction Female sex steroid hormones have been 
implicated in sex-related differences in the development 
and clinical outcomes of asthma. The role of exogenous sex 
steroids, however, remains unclear. Our recent systematic 
review highlighted the lack of high-quality population-
based studies investigating this subject. We aim to 
investigate whether the use of hormonal contraception and 
hormone replacement therapy (HRT), subtypes and route 
of administration are associated with asthma onset and 
clinical outcomes in reproductive age and perimenopausal/
postmenopausal females.
Methods and analysis Using the Optimum Patient Care 
Research Database (OPCRD), a national primary care 
database in the UK, we will construct a retrospective 
longitudinal cohort of reproductive age (16–45 years) and 
perimenopausal/postmenopausal (46–70 years) females. 
We will estimate the risk of new-onset asthma using 
Cox regression and multilevel modelling for repeated 
asthma outcomes, such as asthma attacks. We will adjust 
for confounding factors in all analyses. We will evaluate 
interactions between the use of exogenous sex hormones 
and body mass index and smoking by calculating the relative 
excess risk due to interaction and the attributable proportion 
due to interaction. With 90% power, we need 23 700 
reproductive age females to detect a 20% reduction (risk ratio 
0.8) in asthma attacks for use of any hormonal contraception 
and 6000 perimenopausal/postmenopausal females to detect 
a 40% (risk ratio 1.40) increased risk of asthma attacks for 
use of any HRT.
Ethics and dissemination We have obtained approval 
(ADEPT1317) from the Anonymised Data Ethics and Protocol 
Transparency Committee which grants project-specific ethics 
approvals for the use of OPCRD data. Optimum Patient Care 
has an existing NHS Health Research Authority ethics approval 
for the use of OPCRD data for research (15/EM/150). We will 
present our findings at national and international scientific 
meetings and publish the results in international peer-
reviewed journals.
trial registration number EUPAS22967.
IntroduCtIon
Asthma is more common in boys than girls 
during early childhood.1–3 However, after 
puberty, the prevalence and severity of 
asthma are higher in females than males.1–3 
Female sex steroid hormones are believed, 
at least in part, to explain these sex-related 
variations in asthma outcomes.1–3 Variations 
in asthma incidence and clinical outcomes 
are seen to follow the hormonal transitional 
points in the female reproductive life course, 
in particular, puberty, menarche, menstru-
ation, pregnancy and menopause.1 4 Fluc-
tuations in oestradiol and progesterone 
levels during the menstrual cycle have 
been linked to worsening of asthma symp-
toms in females,5 although immunological 
mechanisms underlying these effects have 
not been clearly defined. In comparison to 
non-menopausal females, transitional meno-
pausal females and both early and late post-
menopausal females were at increased risk 
of new-onset asthma. In primary studies, 
strengths and limitations of this study
 ► The longitudinal nature of this study will fill an im-
portant gap in the evidence base as there is a pau-
city of longitudinal studies investigating the role 
of exogenous sex steroid hormones in asthma in 
females.
 ► As a study based on primary care database, both 
exposure and outcome measures will be objectively 
defined.
 ► This study is based on the general and unselected 
population; therefore, our findings will be general-
isable to the general population of reproductive age 
and perimenopausal/postmenopausal females.
 ► Overall, this study will inform the direction for further 
mechanistic and interventional works.
 ► A limitation of this work is that we will define re-
productive and menopausal status of females based 
only on the ages of women which is the only infor-
mation available from the General Practitioner data-
base for this purpose.
 o
n
 2 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020075 on 27 June 2018. Downloaded from 
2 Nwaru BI, et al. BMJ Open 2018;8:e020075. doi:10.1136/bmjopen-2017-020075
Open access 
the role of menopause on risk of current symptoms of 
asthma were equivocal,6 but a recent meta-analysis of 
these studies showed a moderately increased risk.7 
Both oestrogen and progesterone influence smooth 
muscle functions, inflammation and airway responsive-
ness.8–10 Studies in animal models indicate that oestrogen 
increases T-helper (Th) 2 cell responses associated with 
allergic asthma.10 A recent study showed that in patients 
with severe asthma, both oestrogen and progesterone 
were associated with a decrease in the expression of 
the left-7f microRNA and an increase in interleukin 
(IL)−23/IL-23 receptor signalling and IL-17A produc-
tion, an effect that was more marked in women versus 
men.11 Some evidence suggests that external suppres-
sion of endogenous sex steroid production through the 
use of exogenous hormonal contraception may improve 
asthma outcomes,12–17 whereas the use of hormone 
replacement therapy (HRT) by menopausal women may 
increase the risk of new-onset asthma and risk of poor 
clinical outcomes of asthma.18–23 Females with asthma 
exhibit enhanced Th17 responses, reduced asthma symp-
toms and improved lung function when using hormonal 
contraception.5 9 10 24 25
The role of use of hormonal contraceptives both in the 
development of new-onset asthma23 26 and manifestation 
of current symptoms of asthma16 has been conflicting. 
Using the serial cross-sectional Scottish Health Surveys, 
we recently observed substantial reductions in asthma 
exacerbations and hospital episodes in females using 
hormonal contraception compared with those not using 
hormonal contraception.15 This work was followed by 
a comprehensive synthesis of the underlying evidence 
which revealed inherent methodological limitations 
in previous studies on the topic, including a paucity of 
prospective longitudinal studies and limitations in the 
measurement of sex steroids and asthma outcomes.7 
To overcome these weaknesses and thus clarify whether 
the role of sex steroid hormones in asthma in females is 
causal, well-designed long-term longitudinal studies with 
well-characterised populations are required. We plan to 
investigate the role of exogenous sex steroid hormones 
in the development of asthma and manifestation of clin-
ical and patient-reported outcomes in females by creating 
a retrospective longitudinal cohort of reproductive age 
and perimenopausal/postmenopausal females using the 
Optimum Patient Care Research Database (OPCRD). 
Specifically, we aim to investigate the:
1. Associations between use of hormonal contracep-
tion and asthma onset, attacks, severity, mortality and 
health-related quality of life (HRQoL) in reproduc-
tive-age females.
2. Impact of type of menopause (surgical vs non-surgical) 
and use of HRT on asthma onset, attacks, severity, mor-
tality and HRQoL in perimenopausal/postmenopaus-
al females.
3. Interactions between exogenous sex hormones, body 
mass index (BMI), cigarette smoking and alcohol con-
sumption in these associations.
MEthods
Patient and Public Involvement
In developing the study protocol at the grant application 
stage, we worked closely with the members of the Patient 
and Public Involvement (PPI) group of the Asthma UK 
Centre for Applied Research, University of Edinburgh. 
Selected members of the PPI helped with the grant 
application, including commenting and refining the 
plain English summary of the application, and ensuring 
that the public perspectives are thoroughly embedded 
throughout the research plans. We will also invite the PPI 
group to comment on the findings of the study, play an 
active part in developing the key messages from the study 
for public consumption and help in disseminating our 
findings to the public via website, social media, confer-
ences and public engagement events around the study.
study design and population
OPCRD is a bespoke longitudinal deidentified primary 
care database representing over 600 general practices 
across the UK and is regularly used to conduct epidemi-
ological, clinical and pharmaceutical research (http:// 
optimumpatientcare. org/ opcrd/). A major advantage of 
the OPCRD database is the focus on respiratory outcomes; 
in up to 10% of patients with asthma, patient-reported 
questionnaire data on asthma outcomes are available. 
This provides the opportunity to study both clinical and 
patient-reported outcomes from the database. The study 
population for the present investigation will comprise all 
females aged 16–70 years in OPCRD. We will construct 
two independent cohorts to address the study objectives, 
namely:
1. Reproductive age females (16–45 years of age) to study 
the associations between use of hormonal contracep-
tion and the study outcomes.
2. Perimenopausal (46–55 years)/postmenopausal fe-
males (56–70 years) to study the associations between 
type of menopause and HRT and the study outcomes.
Exposures
We will ascertain the use of hormonal contraception and 
HRT and type of menopause by means of the Read Clin-
ical Classification System (Read codes).27 28 We will define 
the following exposures:
1. Reproductive age females: use of hormonal contracep-
tion versus non-use of hormonal contraception; sub-
types (oestrogen/progestogen combined, progestogen 
only vs non-use of hormonal contraception); route of 
administration (transdermal, subcutaneous, intramus-
cular, local intrauterine vs oral route), and frequency 
and duration of use (as a count exposure).
2. Menopausal status: perimenopausal (46–55 years) ver-
sus non-menopausal (<46 years); postmenopausal (56–
70 years) versus non-menopausal (<46 years)
3. Perimenopausal/postmenopausal females: use of HRT 
versus non-HRT use, subtypes (oestrogen/progesto-
gen combined, oestrogen-only vs non-HRT use), route 
of administration (transdermal, subcutaneous, local 
 o
n
 2 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020075 on 27 June 2018. Downloaded from 
3Nwaru BI, et al. BMJ Open 2018;8:e020075. doi:10.1136/bmjopen-2017-020075
Open access
intrauterine vs oral route), and frequency and dura-
tion of use (as a count exposure).
Confounders
Potential confounders will be extracted from the data-
base using their respective Read codes, including age, 
parity, BMI, smoking, current use of asthma treatments 
and level of adherence to these using our definition 
based on the algorithm developed within the OPCRD,29 
Index of Multiple Deprivation,30 co-morbidity based on 
the Charlson index31 and other indications for use of 
hormonal contraception (eg, endometriosis, polycystic 
ovary syndrome (PCOS), menorrhagia, acne and metror-
raghia) and HRT (eg, onset of menopause, endometriosis 
and indicators for hysterectomy for symptomatic uterine 
fibroids, and heavy menstrual bleeding) besides contra-
ception and symptoms of menopausal transition, respec-
tively. Endometriosis32 and PCOS,33 key indicators for the 
use of hormonal contraceptives among reproductive age 
women, have been linked to risk of asthma and, therefore, 
are important confounders in the association between 
use of hormonal contraceptives and asthma. For HRT, the 
onset of menopause itself and hysterectomy, other indi-
cators for use of HRT besides symptoms of menopausal 
transition, have also been linked to asthma.6 21
outcomes
The primary outcomes will include new-onset asthma, 
asthma attacks and severity. New-onset asthma will be 
defined as the first General Practitioner (GP)-recorded 
asthma event (including diagnosis, hospitalisation, medi-
cation prescription or any other asthma event) occur-
ring at least 5 years from the start of the follow-up date. 
We will exclude individuals with a relevant asthma event 
recorded up to 5 years after the start of follow-up date. 
We assume that within a 5-year period, a patient with 
asthma should have had at least one clinical encounter. 
Asthma attacks and severity will be defined based on the 
frequency of GP consultation, accident and emergency 
attendance, oral steroid courses and hospital admissions 
for asthma. Using these parameters and based on algo-
rithm we have now developed within the OPCRD data-
base, patients will be classified according to the British 
Thoracic Society and Scottish Intercollegiate Guidelines 
Network asthma severity steps.34 The outcomes will be 
determined using relevant Read codes. The secondary 
outcomes will include patient-reported asthma symp-
toms, medication use and HRQoL. Data on HRQoL will 
be assessed from patient-completed questionnaires on 
asthma symptoms and quality of life which is an adjunct 
data collected from about 10% of patients and added to 
the OPCRD database.
Follow-up period
We will follow the participants from baseline starting from 
1 January 2000 or date of registration until 31 December 
2016. With regard to onset of asthma, exit date from 
the cohort will be defined as the date of first diagnosis 
of asthma (ie, date of first record of an asthma event), 
death, deregistration from a practice or end of follow-up 
(31 December 2016), whichever comes first.
statistical analyses
Prior to the main analyses, the data will undergo rele-
vant quality checks, including relevant variable cate-
gorisation (rescaling where appropriate) and checks for 
missingness. We will undertake a complete case anal-
ysis and also perform multiple imputation for variables 
with missing values. We will perform 20 imputations in 
order to enhance the efficiency of the estimates and will 
use Rubin’s rule to combine the estimates across the 20 
datasets.35 Where the specific time of onset of asthma is 
observable, we will perform survival analysis using the 
log-rank test to describe the survival functions of the 
groups as defined by use of sex hormones. We will use 
Cox proportional hazards regression to study the asso-
ciations between exogenous sex hormones and the first 
record of an asthma event. Multilevel modelling will be 
used to estimate associations where the outcomes are 
repeated, for example, number of asthma attacks and 
medication use. Since the change in hormone levels with 
contraceptive use is expected to differ between women, 
random coefficient models will be fitted, so that in turn 
the relationship between contraception use and asthma 
outcomes can differ between women. We will undertake 
analyses incorporating propensity scores using matching 
(exposed vs unexposed).36 The model will be non-par-
simonious in order to include a wide range of factors 
that influence propensity to be prescribed hormonal 
contraceptives and HRT. To minimise potential biases, 
we will undertake different scenarios of sensitivity anal-
yses in order to evaluate the robustness of our findings, 
including analyses for potential selection bias at baseline, 
unmeasured confounding and information bias.37 These 
sets of bias analyses will be aided by deriving relevant 
internal data from a subset of the study population where 
possible. Alternatively, we will obtain external validation 
data (for instance, from the Secure Anonymised Infor-
mation Linkage in Wales) that will provide the basis for 
defining the sensitivities of the different measures and 
allow appropriate adjustments to be made to our esti-
mates. We will also evaluate the potential of confounding 
by indication bias by stratifying the analyses by the rele-
vant disease indication for using sex steroid preparations 
as indicated in the Confounders section. To estimate the 
potential interactions between sex hormones and BMI 
and cigarette smoking, we will calculate the relative excess 
risk due to interaction and the attributable proportion 
due to interaction.38 All estimates will be accompanied by 
their respective 95% CIs. Statistical analyses will be under-
taken using R statistical software.
sample size estimation
Given estimates of our previous exploratory analysis using 
the Scottish Health Surveys (31% using any hormonal 
contraception, 6.5% with clinician-diagnosed asthma and 
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an OR of 0.68, 95% CI 0.47 to 0.98),15 we determined 
that in order to have 90% power at an alpha level of 0.05 
to detect up to 20% reduction (risk ratio 0.8) in asthma 
attacks, we will need a sample size of 23 700 reproduc-
tive age females for use of any hormonal contraception. 
Furthermore, with 90% power at an alpha level of 0.05, 
we determined that we will need 6000 perimenopausal/
postmenopausal females to detect up to 40% (risk ratio 
1.40) increased risk of asthma attack for use of any HRT.23 
Currently, the OPCRD database has over 5 million popula-
tion of patients. We anticipate that about 500 000 patients 
will meet the criteria for inclusion into this study.
reporting and dissemination plans
We will report the findings of the study following the 
recommendations of Strengthening the Reporting of 
Observational Studies in Epidemiology39 and Reporting 
of studies Conducted using Observational Routinely-col-
lected health Data statements.40 All the analysis source 
codes will be made available at GitHub website (https:// 
github. com/ asthmalhs). The project findings will be 
presented at national and international scientific meetings 
and published in international journals. Furthermore, we 
will capitalise on the dissemination infrastructures of the 
Asthma UK Centre for Applied Research (eg, the Twitter 
feed and dynamic website) and the University of Gothen-
burg to publicise our findings to clinicians, academics, 
patients and reproductive health channels.
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